Publications by authors named "M N Yenerel"
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate the expression level of the target genes in the cell. Breast cancer is responsible for the majority of cancer-related deaths among women globally. It has been proven that deregulated miRNAs may play an essential role in the progression of breast cancer.
View Article and Find Full Text PDFThrombotic thrombocytopenic purpura (TTP) is one of the rare group disorders classified as thrombotic microangiopathies (TMAs). Approximately 90% of TTP developed immune-mediation by the formation of antibodies against the enzyme ADAMTS-13. The exact cause is unknown.
View Article and Find Full Text PDFArticle Synopsis
- Crovalimab is a new C5 inhibitor that can be self-administered every four weeks and is being tested in a phase 3 trial against another treatment, eculizumab, for patients with paroxysmal nocturnal hemoglobinuria (PNH).
- The trial's focus shifted from efficacy to safety due to not meeting recruitment goals, and exploratory endpoints included various measures of patient health and satisfaction.
- Results showed that while both treatments had adverse events, crovalimab showed sustained effectiveness and 85% of patients preferred it over eculizumab, suggesting it might be a more manageable treatment option for long-term PNH care.
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.
View Article and Find Full Text PDFIntroduction: This study compared the pharmacokinetics (PK) of the ravulizumab on-body delivery system for subcutaneous (SUBQ) administration with intravenous (IV) ravulizumab in eculizumab-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH).
Methods: Patients with PNH received SUBQ ravulizumab (n = 90) or IV ravulizumab (n = 46) during the 10-week randomized treatment period; all patients then received SUBQ ravulizumab during an extension period (< 172 weeks; data cutoff 1 year). Primary endpoint was day 71 serum ravulizumab trough concentration (C).